BMS yesterday imposed restrictions on 340B pricing on most of its covered outpatient drugs, while liberalizing its policy on access to 340B pricing on its expensive cancer drugs Revlimid, Pomalyst, and Thalomid.

Breaking News

BMS Clamps Down on 340B Contract Pharmacy for Most of its Drugs but Expands 340B Access to its Controversial Myeloma Meds Program

Bristol Myers Squibb (BMS) yesterday became the 12th drug manufacturer to impose restrictions on 340B pricing when hospitals and grantee covered entities contract with pharmacies to dispense drugs to patients.

Please Login or Become a Paid Subscriber to View this Content

If you are already a paid subscriber, please follow the steps below.
If you are not yet a paid subscriber, please Subscribe now.
For questions about subscriptions or technical assistance, please contact Reshma Eggleston at
« Read Previous Read Next »
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors

*Sign up for news summaries and alerts from 340B Report